

Unique Biotech Limited

Instrument	Amount In Rs Crore	Rating Action
Long Term Fund Based Limits	12.98 (revised from Rs 9.80 crore)	[ICRA]BBB-(Stable) / upgraded
Short Term Non-Fund Based Limits	2.50	[ICRA]A3 / upgraded
Long/Short Term Unallocated Limits	6.74 (revised from Rs 9.22 crore)	[ICRA]BBB- (Stable) / [ICRA]A3 upgraded

ICRA has upgraded the long-term rating assigned to the Rs. 12.98 crore (revised from Rs. 9.80 crore)¹ fund based limits of Unique Biotech Limited (UBL)² to **[ICRA]BBB-** (pronounced ICRA triple B minus) from [ICRA]BB+ (pronounced ICRA double B plus). ICRA has also upgraded the short term rating assigned to the Rs. 2.50 crore non-fund based limits of UBL to **[ICRA]A3** (pronounced ICRA A three) from [ICRA]A4+ (pronounced ICRA A four plus). ICRA has also upgraded the ratings assigned to Rs 6.74 crore (revised from Rs. 9.92 crore) unallocated limits of UBL to [ICRA]BBB-/ [ICRA]A3 from [ICRA]BB+/[ICRA]A4+. The outlook on the long term rating is Stable.

The upgrade in ratings factors in healthy growth in operating income with CAGR of 20% during FY2013-FY2016 backed by health demand for the company's probiotic products in the export market and addition of new products in its portfolio and healthy operating margins with improvement in gearing and coverage indicators during FY2016. ICRA also notes that commencement of production from new formulation block for liquid vials from June 2016, increase in capacity of formulation capsules from December 2016 and product registration in various countries for supply of formulations to support revenue growth in the medium term. The ratings also positively takes into account over 15 years of experience of the management in the pharmaceutical industry; niche probiotics product profile with forward integration in the formulation segment.

However, the ratings are constrained by modest scale of operations of UBL with revenues of Rs. 61.57 crore for FY2016; moderate working capital intensity of the business owing to high debtor levels; and moderate customer concentration with top 5 customers contributing 54% of total sales in FY2016. The company has also made significant capex of ~Rs.20 crore during last 2 years and will incur additional ~Rs. 8 crore capex in FY2017 for purchase of machinery with majority of capex being funded by way of internal accruals. Also, the profitability is exposed to forex risk on account of no defined hedging policy in place with company deriving around 50% of revenues from exports.

Going forward, ability of the company to ramp up operations from its new formulation block, maintaining current profitability levels and effectively manage its working capital requirements would remain the key rating sensitivities from credit perspective.

Company Profile

Incorporated in December 2000, UBL is primarily involved in the manufacturing and marketing of probiotics as individual cultures, blends and finished formulations. Although the company is focused on human healthcare, it also manufactures some probiotic strains for poultry, pet animals and livestock in bulk as well as finished formulations. The company markets its products to domestic pharmaceutical companies besides exporting to 33 countries like the US, Europe, Japan, Switzerland, Korea etc. The company is promoted by Dr. M. Ratna Sudha and Dr. R.V.S.K Chakravarthy having more than 15 years of experience in the pharmaceutical industry. UBL is WHO-GMP, ISO 9001: 2008 certified company and its R & D is recognized by DSIR³, Government of India.

Recent Results

As per audited financials for FY2015, UBL reported an operating income of Rs. 52.21 crore with profit after tax of Rs. 8.14 crore and Rs. 61.57 crore of operating income with profit after tax of Rs. 12.06 crore in FY2016 (unaudited and provisional). The company has made sales of ~Rs. 16 crore during Q1, FY2017.

September 2016

¹100 lakh = 1 crore = 10 million

²For complete rating scale and definitions, please refer to ICRA's website http://www.icra.in or other ICRA Rating

³ DSIR: Department of Scientific and Industrial Research



For further details please contact:

<u>Analyst Contacts:</u>

Mr. K. Ravichandran, (Tel. No. +91-44-45964301)
ravichandran@icraindia.com

R Srinivasan (Tel. No. +91 44 4596 4315) r.srinivasan@icraindia.com

<u>Relationship Contacts:</u> **Mr. Jayanta Chatterjee** (Tel. No. +91-80-43326401) jayantac@icraindia.com

© Copyright, 2016, ICRA Limited. All Rights Reserved Contents may be used freely with due acknowledgement to ICRA

ICRA ratings should not be treated as recommendation to buy, sell or hold the rated debt instruments. ICRA ratings are subject to a process of surveillance, which may lead to revision in ratings. An ICRA rating is a symbolic indicator of ICRA's current opinion on the relative capability of the issuer concerned to timely service debts and obligations, with reference to the instrument rated. Please visit our website www.icra.in or contact any ICRA office for the latest information on ICRA ratings outstanding. All information contained herein has been obtained by ICRA from sources believed by it to be accurate and reliable, including the rated issuer. ICRA however has not conducted any audit of the rated issuer or of the information provided by it. While reasonable care has been taken to ensure that the information herein is true, such information is provided 'as is' without any warranty of any kind, and ICRA in particular, makes no representation or warranty, express or implied, as to the accuracy, timeliness or completeness of any such information. Also, ICRA or any of its group companies may have provided services other than rating to the issuer rated. All information contained herein must be construed solely as statements of opinion, and ICRA shall not be liable for any losses incurred by users from any use of this publication or its contents.



Registered Office ICRA Limited

1105, Kailash Building, 11th Floor, 26, Kasturba Gandhi Marg, New Delhi 110001 Tel: +91-11-23357940-50, Fax: +91-11-23357014

Corporate Office Mr. Vivek Mathur

Mobile: +91 9871221122 Email: vivek@icraindia.com

Email: jayantac@icraindia.com

Tel:- +91-40-40676500

Bhavan Road, Hyderabad—500083

4th Floor, Shobhan, 6-3-927/A&B. Somajiguda, Raj

Building No. 8, 2nd Floor, Tower A, DLF Cyber City, Phase II, Gurgaon 122002 Ph: +91-124-4545310 (D), 4545300 / 4545800 (B) Fax; +91-124-4050424

Mumbai Kolkata Mr. L. Shivakumar Mr. Jayanta Roy Mobile: +91 9903394664 Mobile: +91 9821086490 Email: shivakumar@icraindia.com Email: jayanta@icraindia.com 3rd Floor, Electric Mansion A-10 & 11, 3rd Floor, FMC Fortuna Appasaheb Marathe Marg, Prabhadevi 234/3A, A.J.C. Bose Road Mumbai-400025, Kolkata—700020 Board: +91-22-61796300; Fax: +91-22-24331390 Tel +91-33-22876617/8839 22800008/22831411, Fax +91-33-22870728 Chennai Bangalore Mr. Jayanta Chatterjee Mr. Jayanta Chatterjee Mobile: +91 9845022459 Mobile: +91 9845022459 Email: jayantac@icraindia.com Email: jayantac@icraindia.com 5th Floor, Karumuttu Centre 'The Millenia' 634 Anna Salai, Nandanam Tower B, Unit No. 1004,10th Floor, Level 2 12-14, 1 & 2, Chennai-600035 Murphy Road, Bangalore 560 008 Tel: +91-44-45964300; Fax: +91-44 24343663 Tel: +91-80-43326400; Fax: +91-80-43326409 Ahmedabad Pune Mr. L. Shivakumar Mr. L. Shivakumar Mobile: +91 9821086490 Mobile: +91 9821086490 Email: shivakumar@icraindia.com Email: shivakumar@icraindia.com 907 & 908 Sakar -II, Ellisbridge, 5A, 5th Floor, Symphony, S.No. 210, CTS 3202, Range Ahmedabad- 380006 Hills Road, Shivajinagar, Pune-411 020 Tel: +91-79-26585049, 26585494, 26584924; Fax: Tel: + 91-20-25561194-25560196; Fax: +91-20-+91-79-25569231 25561231 Hvderabad Mr. Jayanta Chatterjee Mobile: +91 9845022459